Drug intelligence / Profile preview

CD19-targeting CAR T cells (Fuda Cancer Hospital)

Development stage
Unknown
Lead developer
Fuda Cancer Hospital
Modality
CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration
Intravenous
01

Overview

CD19-targeting CAR T cells (Fuda Cancer Hospital) is an autologous, second-generation chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of B-cell malignancies. The therapy involves the ex vivo genetic modification of a patient's own T lymphocytes to express a CAR specific for the CD19 antigen, a surface protein consistently expressed on B-cell lymphomas. Upon re-infusion, these engineered cells recognize and bind to CD19-positive cells, triggering T-cell activation, proliferation, and the targeted destruction of the malignant B cells. It is currently being investigated in clinical trials for patients with relapsed or refractory B-cell lymphoma.

Other names
CD19-targeting 2nd generation CAR T cellsCD-19-targeting 2nd generation CAR T cellsCD 19-targeting 2nd generation CAR T cellsCD19 CAR-T cellsCD-19 CAR-T cellsCD 19 CAR-T cells
02

Targets

Beyond the preview

Go deeper on CD19-targeting CAR T cells (Fuda Cancer Hospital).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19-targeting CAR T cells (Fuda Cancer Hospital).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call